Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
, 76 (5), 477.e16-20

Intracranial Meningiomas in Patients With Uterine Sarcoma Treated With Long-Term Megestrol Acetate Therapy

Affiliations
Case Reports

Intracranial Meningiomas in Patients With Uterine Sarcoma Treated With Long-Term Megestrol Acetate Therapy

Thomas J Gruber et al. World Neurosurg.

Abstract

Objective: To report a series of four patients with uterine sarcoma, including one with müllerian adenosarcoma (MA) and three with low-grade endometrial stromal sarcoma (LGESS), who developed intracranial meningiomas while receiving the progesterone agonist megestrol acetate.

Methods: The hospital records, imaging studies, and pathology slides of four patients who were treated for uterine sarcomas and subsequently developed intracranial meningiomas were reviewed.

Results: All patients underwent surgery for their gynecologic cancers and received maintenance therapy with long-term hormonal suppression with megestrol acetate. Each of the four patients later developed neurologic symptoms secondary to intracranial meningiomas. Three patients had more than one meningioma. Histopathologic examination of all excised tumors showed strong immunoreactivity for progesterone receptors (PRs).

Conclusions: Patients with uterine sarcoma subtypes LGESS and MA may be predisposed to develop meningiomas, particularly in the setting of long-term treatment with megestrol acetate. Alternatively, preexisting, clinically silent meningiomas in these patients may have progressed to the point of clinical symptoms in the presence of the progesterone agonist megestrol acetate. Without previous imaging studies showing the presence or absence of meningioma before initiation of megestrol acetate treatment, there is no way to draw definitive conclusions regarding this possibility. Clinical and neuroradiologic surveillance for meningiomas should be strongly considered in patients with these uterine sarcoma subtypes, particularly in patients undergoing long-term suppressive therapy with megestrol acetate.

Comment in

Similar articles

See all similar articles

Cited by 3 PubMed Central articles

  • Treatment of Recurrent or Metastatic Uterine Adenosarcoma
    MJ Nathenson et al. Sarcoma 2017, 4680273. PMID 29445312.
    These results suggest that surgery is an important treatment modality for recurrent or metastatic uterine adenosarcoma, and the most effective chemotherapeutics are doxor …
  • Uterine Adenosarcoma: A Review
    MJ Nathenson et al. Curr Oncol Rep 18 (11), 68. PMID 27718181. - Review
    Adenosarcomas are rare malignancies of the female genital tract, accounting for approximately 5 % of uterine sarcomas. Occasionally, adenosarcoma occurs in the ovaries or …
  • Regression of Intracranial Meningioma During Treatment With α1-Adrenoceptor Blocker
    EA Hoegestoel et al. J Neurol Surg Rep 77 (1), e62-5. PMID 27175325. - Case Reports
    Background Regression of meningioma has been reported after hemorrhage or hormonal withdrawal. Here, we report a case of an incidentally diagnosed meningioma that regress …

Publication types

MeSH terms

Substances

Feedback